The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Clinical Roundup

Early positive results from phase II DPX-Survivac + Keytruda in DLBCL

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

IMV Inc. announced that investigators are evaluating IMV’s lead candidate, DPX-Survivac, in combination with low dose cyclophosphamide and Merck’s checkpoint inhibitor Keytruda (pembrolizumab), in patients with persistent or recurrent/refractory diffuse large B-cell lymphoma.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Trump administration seeks to slash NIH by roughly 40% as 27 institutes and centers are whittled down to eight
NCI to remain intact, but its finances are uncertain; FDA is spared big cuts

Confidential Trump administration budget documents show that the upcoming FY26 Budget Request will radically cut about $50 billion out of the U.S. Department of Health and Human Services, reshuffling agency components, and slashing the number of NIH institutes and centers to just eight. 
By Paul Goldberg
Cancer Policy

NCI summarizes changes to the CCSG NOFO

In an email sent to directors and deputy directors of NCI-designated cancer centers, ​​Krzysztof Ptak, director of the NCI Office of Cancer Centers, provided a comparison between the newly issued Cancer Center Support Grant Notice of Funding Opportunity with the previous version of the document.
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account